Gilead’s CAR-T therapy prolongs survival in key blood cancer trial – STAT News
Yescarta is the first CAR-T to show longer survival for this blood cancer in a randomized study, another milestone for the therapy.
Yescarta is the first CAR-T to show longer survival for this blood cancer in a randomized study, another milestone for the therapy.